A. TRATAMENTO COM HCQ ISOLADA OU ASSOCIADA A AZ PARA COVID-19 - ESTUDOS CLINICOS COM RESULTADO DESFAVORÁVEL AO USO E SEM BENEFÍCIO.

1- Siemieniuk, et al Drug treatments for covid-19: living systematic review and network meta-analysis, Reed AC, BMJ 2020;370:m2980
http://dx.doi.org/10.1136/bmj.m2980


2-NIH - Medicamentos antivirais aprovados ou em avaliação para o tratamento de COVID-19. Última atualização: 3 de novembro de 2020
https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/

3-Omrani et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100645 (Peer Reviewed)
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.

4-Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646 (Peer Reviewed)
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda.

4-RECOVERY Collaborative Group Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19.

6-Mitjà et al., Clinical Infectious Diseases, ciaa1009, doi:10.1093/cid/ciaa1009 (Peer Reviewed)
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.

7-Kuderer et al., Lancet, June 20, 2020, doi:10.1016/S0140-6736(20)31187-9 (preprint 5/28) (Peer Reviewed)

8-Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457 (Peer Reviewed) ICU and ventilator mortality among critically ill adults with COVID-19.


Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.

14-Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268 (Peer Reviewed)
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results.

16-Choi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.062 (Peer Reviewed)
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.

Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.

18-Laplana et al., PLOS ONE, doi:10.1371/journal.pone.0243598 (Peer Reviewed)
Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.

Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.

20-Molina JM et al, Medicine et Maladies Infectieuses - No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.  
https://doi.org/10.1016/j.medmal.2020.03.006

21-Skipper CP et al Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial - Skipper CP et al, June 2020  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384270/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523161/


24-Borba MGS et al JAMA Netw 2020 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionA Randomized Clinical Trial;  
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499

25- Gautret, P et al Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.  
https://doi.org/10.1016/j.ijantimicag.2020.106241
26- Guisado-Vasco (Peer Reviewed)
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30335-7/fulltext

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

28- Sarfaraz S et al, Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan


30- Psevdos G et al Corona Virus Disease-19 (COVID-19) in a Veterans Affairs Hospital at Suffolk County, Long Island- New York
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778163/

31- Barnabas, VR et al, Hidrocicloroquina como profilaxia pós-exposição para prevenir a infecção por Coronavirus 2 com síndrome respiratória aguda: Um ensaio randomizado
32-Nachega et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240 (Peer Reviewed)
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
https://www.ajtmh.org/view/journals/tpmd/103/6/article-p2419.xml?tab_body=fulltext

https://doi.org/10.1002/phar.2467

34- Tehrani et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.071 (Peer Reviewed)
Risk factors for mortality in adult COVID-19 patients; frailty predicts fatal outcome in older patients.

35-Self et al., JAMA, doi:10.1001/jama.2020.22240 (Peer Reviewed)
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
https://jamanetwork.com/journals/jama/fullarticle/2772922

COVID-19 in hospitalized patients in Spain: a cohort study in Madrid.

37-Alqassieh et al., F1000Research, Preprint (Preprint)
Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan.
https://f1000research.com/articles/9-1439/v1
38-Vernaz et al., Swiss Medical Weekly, doi:10.4414/smw.2020.20446 (Peer Reviewed)
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.

39-Chari et al., Blood, doi:10.1182/blood.2020008150 (Peer Reviewed)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.

Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent Infection With SARS-CoV-2: Insights From a Large Healthcare Database Analysis.


Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
43- Revollo et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa477 (Peer Reviewed)
Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers.
https://doi.org/10.1093/jac/dkaa477

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.


Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
49- Rentsch et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30378-7
https://www.medrxiv.org/content/10.1101/2020.09.04.20187781v1 (Peer Reviewed)
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.

50- Li et al., Research Square, doi:10.21203/rs.rs-119202/v1 (Preprint)
Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis.

B. TRATAMENTO COM HCQ ISOLADA OU ASSOCIADA A AZ PARA COVID-19 - ESTUDOS CLINICOS COM RESULTADO FAVORÁVEL AO USO.


3- Lagier J-C et al, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine azithromycin and other regimens in Marseille, France: A retrospective analysis – Travel Medicine and Infectious Disease-


4- Fonseca SNS et al, Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis - Travel Medicine and Infectious Disease.
https://doi.org/10.1016/j.tmaid.2020.101906


https://doi.org/10.1016/j.ijantimicag.2020.106214

6-Ly et al., International Journal of Antimicrobial Agents,
Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France.


Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19.
9-Huang et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113 (Peer Reviewed)

Risk Factors for Mortality in Patients with COVID-19 in New York City.

Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.

Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid.

13- Berenguer et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.07.024 (Peer Reviewed)

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.

Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19.
16-Pinato et al., Cancer Discovery, doi:10.1158/2159-8290.CD-20-0773 (Peer Reviewed)
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.

17-Gonzalez et al., medRxiv, doi:10.1101/2020.08.18.20172874 (Preprint)

Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants.

19-Di Castelnuovo et al., European J. Internal Medicine, doi:10.1016/j.ejim.2020.08.019 (Peer Reviewed)
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.

20-Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860 (Peer Reviewed)
Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients.

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.

22-Ayerbe et al., Internal and Emergency Medicine, doi:0.1007/s11739-020-02505-x (Peer Reviewed) The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.


28-Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1 (Preprint) Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study.


COVID-19 in hospitalized patients in Spain: a cohort study in Madrid.

33-Signes-Costa et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012 (Peer Reviewed)
Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases.

34-Taccone et al., The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019 (Peer Reviewed)
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium.


36-Bhattacharya et al., medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers.

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study.

39-Zhong et al., Lancet Rheumatology, 10.1016/S2665-9913(20)30227-7 (Peer Reviewed) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.


41-Ferri et al., Clinical Rheumatology, doi:10.1007/s10067-020-05334-7 (Peer Reviewed) COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.


47-Singh et al., medRxiv, doi:10.1101/2020.05.12.20099028 (Preprint)
Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network.


49-D'Arminio Monforte et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.07.056
Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?


1-Espitia-Hernandez et al., Biomedical Research, 31:5 (Peer Reviewed) Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study

2- Shouman et al., Journal of Clinical and Diagnostic Research, doi:10.7860/JCDR/2020/46795.0000 (Peer Reviewed) Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial
3- Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint)
Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full-text

4- Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2 (Preprint)
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
https://www.researchsquare.com/article/rs-100956/v1

5- Preliminary meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection Authors: Andrew Hill on behalf of the International Ivermectin Project Team*
https://assets.researchsquare.com/files/rs-148845/v1_stamped.pdf

D. TRATAMENTO IVM ISOLADA OU ASSOCIADA PARA COVID-19-
ESTUDOS CLINICOS COM RESULTADOS INCONCLUSIVOS MAS PROMISSORES.

1- Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
(preprint 12/7) (Peer Reviewed)
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext

2- Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066 (Preprint)
Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru
https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1

3- Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2
4- Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint)
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
https://www.researchsquare.com/article/rs-109670/v1

5- Kirti et al., medRxiv, doi:10.1101/2021.01.05.21249310 (Preprint)
Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial
https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1